Radar›Companies›Biological Products, Excluding Disgnostic Substances Stocks in USA: Prism Readiness Cohort 3
United States biological products, excluding disgnostic substances industry landscape illustrating listed-company operations, infrastructure and market activity
Prism Finance USA · comparison snapshot

Biological Products, Excluding Disgnostic Substances Stocks in USA: Prism Readiness Cohort 3

A five-company biological products, excluding disgnostic substances cohort selected by Prism readiness, then compared across market path, filings, profitability, readiness, Prism attention and industry context.

Snapshot: 01 September 2026Not investment adviceRanked by Prism readiness
Readiness leaderAligos Therapeutics · 51
Strongest available pathADMA Biologics · +725.7%
Widest latest marginBioCryst · 30.2%
Companies compared5 · U.S.-listed
01 · Readiness ranking

Five companies, one comparable score

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Readiness #1ALGS · Nasdaq

Aligos Therapeutics

A U.S.-listed issuer classified by the SEC in Biological Products, Excluding Disgnostic Substances

Founded 2018San Francisco, California$38.0M market cap
View full Companies Radar profile
51Moderate
Snapshot price$6.09as of page date
Monthly-close return-98.4%five-year window
FY2025 revenue$0.00BAligos Therapeutics, Inc.
Net margin-1106.7%FY2025
P/E snapshot-1.2xone ratio, not a verdict
Prism attention13.3%share across these five
Filing track recordRevenue, USD billions
-64.7%
$0$0.0B$0.0B$0.0BFY2023: $0.006BFY2024: $0.004BFY2025: $0.002B202320242025
FY2023–FY2025 · 3 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR -40.6%
52-week position22% through range
$3.98$13.69
News mentions620
Community mentions7partial coverage
U.S.-scope patents503
Prism Insights

What sits behind the readiness signal

Observed risk 0/100higher means more observed risk
Earnings signal75/100
Management stability90/100
Market position21/100
Capital-event signal44/100
Innovation pulse0/100
Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 0 M&A involvements, 0 asset-acquisition events and 2 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #2ADMA · Nasdaq

ADMA Biologics

A U.S.-listed issuer classified by the SEC in Biological Products, Excluding Disgnostic Substances

Founded 2005Ramsey, New Jersey$2.09B market cap
View full Companies Radar profile
50Moderate
Snapshot price$9.33as of page date
Monthly-close return+725.7%five-year window
FY2025 revenue$0.51BADMA BIOLOGICS, INC.
Net margin28.8%FY2025
P/E snapshot13.3xone ratio, not a verdict
Prism attention14.4%share across these five
Filing track recordRevenue, USD billions
+530.3%
$0$0.2B$0.3B$0.5BFY2021: $0.081BFY2022: $0.154BFY2023: $0.258BFY2024: $0.426BFY2025: $0.510B20212022202320242025
FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 58.4%
52-week position16% through range
$7.21$20.46
News mentions672
Community mentions0partial coverage
U.S.-scope patents51
Prism Insights

What sits behind the readiness signal

Observed risk 0/100higher means more observed risk
Earnings signal51/100
Management stability90/100
Market position18/100
Capital-event signal72/100
Innovation pulse15/100
Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 7 M&A involvements, 5 asset-acquisition events and 3 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #3BCRX · Nasdaq

BioCryst

A U.S.-listed issuer classified by the SEC in Biological Products, Excluding Disgnostic Substances

Founded 1986Durham, North Carolina$2.53B market cap
View full Companies Radar profile
50Moderate
Snapshot price$9.92as of page date
Monthly-close return-31.0%five-year window
FY2025 revenue$0.88BBIOCRYST PHARMACEUTICALS INC
Net margin30.2%FY2025
P/E snapshot10.6xone ratio, not a verdict
Prism attention37.6%share across these five
Filing track recordRevenue, USD billions
+456.6%
$0$0.3B$0.6B$0.9BFY2021: $0.157BFY2022: $0.271BFY2023: $0.331BFY2024: $0.451BFY2025: $0.875B20212022202320242025
FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 53.6%
52-week position75% through range
$6.00$11.22
News mentions1.8K
Community mentions0partial coverage
U.S.-scope patents1047
Prism Insights

What sits behind the readiness signal

Observed risk 7/100higher means more observed risk
Earnings signal68/100
Management stability90/100
Market position16/100
Capital-event signal75/100
Innovation pulse0/100
Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 14 M&A involvements, 1 asset-acquisition events and 4 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

Recent available records contain 0 lawsuit, 2 regulatory and 0 layoff events across their stated windows.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #4IOVA · Nasdaq

Iovance

A U.S.-listed issuer classified by the SEC in Biological Products, Excluding Disgnostic Substances

Founded 2007San Carlos, California$3.75B market cap
View full Companies Radar profile
50Moderate
Snapshot price$8.28as of page date
Monthly-close return-66.4%five-year window
FY2025 revenue$0.26BIOVANCE BIOTHERAPEUTICS, INC.
Net margin-148.4%FY2025
P/E snapshot-28.8xone ratio, not a verdict
Prism attention24.6%share across these five
Filing track recordRevenue, USD billions
+22061.6%
$0$0.1B$0.2B$0.3BFY2023: $0.001BFY2024: $0.164BFY2025: $0.264B202320242025
FY2023–FY2025 · 3 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 1388.7%
52-week position86% through range
$1.76$9.36
News mentions1.2K
Community mentions0partial coverage
U.S.-scope patents897
Prism Insights

What sits behind the readiness signal

Observed risk 4/100higher means more observed risk
Earnings signal74/100
Management stability90/100
Market position0/100
Capital-event signal59/100
Innovation pulse10/100
Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 0 M&A involvements, 0 asset-acquisition events and 0 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

Recent available records contain 0 lawsuit, 1 regulatory and 0 layoff events across their stated windows.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #5GLUE · Nasdaq

Monte Rosa Therapeutics

A U.S.-listed issuer classified by the SEC in Biological Products, Excluding Disgnostic Substances

Founded 2020Cambridge, Massachusetts$1.22B market cap
View full Companies Radar profile
50Moderate
Snapshot price$14.31as of page date
Monthly-close return-35.8%five-year window
FY2025 revenue$0.12BMonte Rosa Therapeutics, Inc.
Net margin-31.2%FY2025
P/E snapshot-7.6xone ratio, not a verdict
Prism attention10.1%share across these five
Filing track recordRevenue, USD billions
+63.5%
$0$0.0B$0.1B$0.1BFY2024: $0.076BFY2025: $0.124B20242025
FY2024–FY2025 · 2 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 63.5%
52-week position46% through range
$4.60$25.77
News mentions472
Community mentions5partial coverage
U.S.-scope patents46
Prism Insights

What sits behind the readiness signal

Observed risk 0/100higher means more observed risk
Earnings signal69/100
Management stability90/100
Market position0/100
Capital-event signal71/100
Innovation pulse0/100
Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 0 M&A involvements, 0 asset-acquisition events and 2 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

02 · Side-by-side

The comparisons that change the picture

Every bar preserves its own meaning. Price return, revenue scale, profitability and attention are deliberately not blended into one recommendation.

Available monthly-close return

Dated window printed on each company card; not a forecast.

ADMA Biologics
+725.7%
BioCryst
-31.0%
Monte Rosa Therapeutics
-35.8%
Iovance
-66.4%
Aligos Therapeutics
-98.4%

Latest revenue

USD billions, official filing scope shown on each company card.

BioCryst
$0.88B
ADMA Biologics
$0.51B
Iovance
$0.26B
Monte Rosa Therapeutics
$0.12B
Aligos Therapeutics
$0.00B

Latest profit margin

Company-card labels distinguish continuing-operations and net-income scope.

BioCryst
30.2%
ADMA Biologics
28.8%
Monte Rosa Therapeutics
-31.2%
Iovance
-148.4%
Aligos Therapeutics
-1106.7%

Prism news attention

Normalized share across these five names; attention is not quality.

BioCryst
37.6%
Iovance
24.6%
ADMA Biologics
14.4%
Aligos Therapeutics
13.3%
Monte Rosa Therapeutics
10.1%
03 · Prism readout

What the signals say—and what they do not

The headline share is normalized biological products, excluding disgnostic substances news attention across these five names. Partial community coverage and U.S.-scope patent records are displayed separately and are not blended into it.

Scale + attention

BioCryst leads the conversation

It holds 37.6% of measured biological products, excluding disgnostic substances news attention and also carries the basket's largest revenue base at $0.88B.

Price path

ADMA Biologics leads the available price paths

Its monthly-close return is +725.7% for the five-year window. At the other end, Aligos Therapeutics is -98.4% for its five-year window. Windows printed on each card must be compared carefully; price history is not a forecast.

Profitability

BioCryst has the widest latest margin

Its FY2025 net margin is 30.2%. Its revenue history in this snapshot spans only the periods printed on its card, so longer histories are not treated as equivalent.

Price vs operating signals

Iovance shows why one ratio is not a verdict

It has the basket's lowest snapshot P/E at -28.8x while its five-year window price return is -66.4%. Valuation, price path and readiness answer different questions.

04 · Research areas

Deeper Prism readout where coverage is dense

Shown only for companies with more than 800 available Prism news records. Counts describe the available research corpus, not company quality.

Areas of research · BCRX

BioCryst

1,762available Prism news records

Prism top themes

Capital allocation & transactions
64
Price action & investor response
50
Leadership & governance
33
Earnings & financial performance
24
Legal, arbitration & regulatory
23

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

-36.1%242 latest 12m vs 379 prior 12m
2024-01: 13 mentions2024-02: 16 mentions2024-03: 21 mentions2024-04: 10 mentions2024-05: 24 mentions2024-06: 9 mentions2024-07: 14 mentions2024-08: 6 mentions2024-09: 14 mentions2024-10: 18 mentions2024-11: 20 mentions2024-12: 4 mentions2025-01: 8 mentions2025-02: 230 mentions2025-03: 8 mentions2025-04: 18 mentions2025-05: 24 mentions2025-06: 15 mentions2025-07: 19 mentions2025-08: 25 mentions2025-09: 13 mentions2025-10: 33 mentions2025-11: 20 mentions2025-12: 18 mentions2026-01: 20 mentions2026-02: 22 mentions2026-03: 14 mentions2026-04: 30 mentions2026-05: 26 mentions2026-06: 2 mentions2024-012026-06

Machine-classified coverage tone

91.4% positive+3.2 pp vs preceding four quarters
24Q3
24Q4
25Q1
25Q2
25Q3
25Q4
26Q1
26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

orphan drug pricing 26orphan drug incentives 19biosimilar approval 13company valuation 13stock performance 12viral vector vaccines 11adc therapeutics 10biosimilar market entry 10

Keyword tag occurrences in available Prism news records.

Coverage: 2010-01-06–2026-06-12 · trend and themes shown through 2026-06
Areas of research · IOVA

Iovance

1,153available Prism news records

Prism top themes

Price action & investor response
46
Legal, arbitration & regulatory
44
Leadership & governance
23
Capital allocation & transactions
16
Earnings & financial performance
12

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

+31.7%241 latest 12m vs 183 prior 12m
2023-12: 0 mentions2024-01: 13 mentions2024-02: 71 mentions2024-03: 13 mentions2024-04: 7 mentions2024-05: 26 mentions2024-06: 5 mentions2024-07: 6 mentions2024-08: 13 mentions2024-09: 6 mentions2024-10: 4 mentions2024-11: 15 mentions2024-12: 6 mentions2025-01: 14 mentions2025-02: 53 mentions2025-03: 16 mentions2025-04: 13 mentions2025-05: 32 mentions2025-06: 31 mentions2025-07: 35 mentions2025-08: 15 mentions2025-09: 16 mentions2025-10: 20 mentions2025-11: 15 mentions2025-12: 12 mentions2026-01: 6 mentions2026-02: 32 mentions2026-03: 18 mentions2026-04: 24 mentions2026-05: 17 mentions2023-122026-05

Machine-classified coverage tone

81.3% positive+1.5 pp vs preceding four quarters
24Q3
24Q4
25Q1
25Q2
25Q3
25Q4
26Q1
26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

immunotherapy 61tumor microenvironment 52cell-based therapies 20stock performance 16angiogenesis inhibitors 15cancer biomarkers 12car-t myeloma 8immunomodulatory drugs 7

Keyword tag occurrences in available Prism news records.

Coverage: 2013-09-26–2026-05-29 · trend and themes shown through 2026-05
05 · Community discussion

Common topics where conversation clears the gate

Shown only above 25 entity-matched mentions. Coverage is partial and topic counts exclude identified namesake noise.

06 · Company event log

Common news types and recent highlights

Event patterns and selected recent headlines come from available Prism company-event records since 2023. Obvious forecast, holdings, duplicate and retrospective noise is filtered.

ALGS

Aligos Therapeutics

through 2026-04-17
Earnings releases 31Company announcements 6Leadership changes 4Business contracts 1
  1. Business contracts

    Aligos Therapeutics has signed an exclusive licence agreement with Xiamen Amoytop Biotech for the development and commercialisation of pevifoscorvir sodium in Greater China for chronic hepatitis B virus (HBV) infection.

  2. Earnings releases

    Based on Aligos Therapeutics’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $741 thousand and a GAAP net loss of $31.54 million.

  3. Company announcements

    Shares of Aligos Therapeutics Inc. (NASDAQ:ALGS) were trading at $10.70, down $3.46, or 24%, after the South San Francisco-based firm disclosed top‑line results from the phase IIa Herald study of ALG‑055009, a thyroid hormone receptor beta agonist, in metabolic‑dysfunction associated steatohepatitis (MASH) subjects.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

ADMA

ADMA Biologics

through 2026-01-20
Earnings releases 33Lawsuits 5Company announcements 2Leadership changes 2Listing / IPO 2
  1. M&A

    New York State Teachers Retirement System boosted its holdings in shares of ADMA Biologics by 0.3% during the second quarter. New York State Teachers Retirement System now owns 222,461 shares of the biotechnology company’s stock worth $4,051,000 after acquiring an additional 571 shares during the period.

  2. Earnings releases

    Grossman also provided preliminary, unaudited full-year 2025 expectations of greater than $510–$511 million in revenue, $235 million of EBITDA, and greater than $158 million of net income.

  3. Company announcements

    ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics, today provided a statement on the recent tariffs put in place and reiterated ADMA’s strategic advantage through fully U.S.-based manufacturing operations, commercialization and end-market sales, and a vertically integrated U.S.-based supply chain.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

BCRX

BioCryst

through 2026-05-04
Earnings releases 34Leadership changes 7M&A 5Company announcements 4Listing / IPO 4
  1. Regulatory

    BioCryst Pharmaceutical, Inc. today announced that it entered into a license agreement granting an Irish affiliate of Neopharmed Gentili exclusive rights to commercialize navenibart for hereditary angioedema (HAE) in Europe.

  2. Earnings releases

    BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today reported financial results for the full year ended December 31, 2025, and provided a business update.

  3. M&A

    Sidley represented Astria Therapeutics, Inc., a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, in its definitive agreement to be acquired by BioCryst Pharmaceuticals, Inc., a global biotechnology company. The transaction values Astria at approximately US$920 million.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

IOVA

Iovance

through 2026-02-24
Earnings releases 19Lawsuits 3Company announcements 2Leadership changes 2Listing / IPO 2
  1. Earnings releases

    On February 24, 2026, Iovance Biotherapeutics reported that 2025 was its first full calendar year of Amtagvi launch, delivering about 30% sequential fourth-quarter revenue growth to roughly $87 million and full-year product revenue of about $264 million, in line with guidance.

  2. Regulatory

    Health Canada's conditional approval of Amtagvi for melanoma treatment

  3. Lawsuits

    class action lawsuit was filed by investors who incurred losses exceeding $100,000.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

GLUE

Monte Rosa Therapeutics

through 2025-05-27
Leadership changes 3Business contracts 2Earnings releases 1
  1. Earnings releases

    Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Monte Rosa Therapeutics $159.49 million 1.53 -$135.35 million $0.08 49.63 Aptose Biosciences N/A N/A -$51.21 million ($89.19) N/A

  2. Business contracts

    Novartis has agreed to pay Monte Rosa $150 million up front, and the latter could bank as much as $2.1 billion in development, regulatory, and sales milestone rewards, beginning upon the start of phase II work, as well as tiered royalties on ex-U.S. net sales.

  3. Leadership changes

    Jennifer Champoux, promoted to Chief Operating Officer, joined Monte Rosa as Vice President of Operations, leading overall corporate operations and Human Resources.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

07 · Industry landscape

Biological Products, Excluding Disgnostic Substances Industry in USA

A bottom-of-page sector lens combining Prism's exact U.S. market-growth extraction with tightly matched U.S.-primary biological products, excluding disgnostic substances news. It adds context to the stock basket without turning industry signals into a recommendation.

Prism market forecast extraction

biologics market

26 sources67.0% extraction confidence
2020 extracted base$194.20B–$477.15B
2033 extracted forecast$685.30B–$1.37T
Implied source CAGR8.5%
high demand for the treatment of different disease indicationsTechnologyadvancements in biotechnology

Multi-source card returned by Prism's /special_extraction market-growth service. Extracted geography mix: Global, Asia Pacific, North America, Mexico. This is a dated market benchmark, not a forecast for the five-stock basket.

Prism news insights

U.S. Biological Products, Excluding Disgnostic Substances news pulse

24,998available Prism news records
Latest 12m volume+9.8%10786 vs 9825 records
Positive classified tone41.7%+4.6 pp vs prior four quarters
2024-01: 892 mentions2024-02: 804 mentions2024-03: 821 mentions2024-04: 790 mentions2024-05: 1,080 mentions2024-06: 758 mentions2024-07: 563 mentions2024-08: 879 mentions2024-09: 628 mentions2024-10: 779 mentions2024-11: 620 mentions2024-12: 655 mentions2025-01: 712 mentions2025-02: 1,067 mentions2025-03: 1,362 mentions2025-04: 999 mentions2025-05: 803 mentions2025-06: 593 mentions2025-07: 966 mentions2025-08: 3,062 mentions2025-09: 751 mentions2025-10: 687 mentions2025-11: 634 mentions2025-12: 660 mentions2026-01: 312 mentions2026-02: 1,077 mentions2026-03: 634 mentions2026-04: 1,323 mentions2026-05: 87 mentions2024-012026-05
24Q4
25Q1
25Q2
25Q3
25Q4
26Q1
26Q2
26Q3

Available U.S.-primary Prism records matching biological, disgnostic, excluding, substance, biologic. Metadata counts can overlap; coverage volume and tone are not measures of industry output.

Recurring Prism themes

harm reduction strategies
4,078
substance abuse education
3,736
opioid addiction and treatment
3,643
overdose prevention techniques
3,482
controlled substance regulations
3,381
substance abuse overdose fatalities
3,287

Metadata occurrences; one record can contribute more than one theme.

Frequent industry keywords

mind-altering drug consumption 1,795opioid diversion abuse 1,702fentanyl treatment programs 1,649drug overdose 1,576cannabis policy reform discussions 1,328psychedelic mental health studies 1,328medication-assisted treatment opioids 1,265psychoactive drug intake 1,170

Counts cover the matched industry corpus, not the broader company-news totals above.

Curated signal map

Opportunity and caution, side by side

Evidence prompts—not probabilities.

Opportunity · market driver

high demand for the treatment of different disease indications

26 forecast sources

A recurring driver in the extracted market evidence provides a measurable research thread for the sector.

Prism /special_extraction market-growth card
Opportunity · demand

harm reduction strategies

4,078 matched theme records

The largest current Prism news theme shows where sector attention and reported activity are concentrating.

Prism U.S. news metadata
Opportunity · innovation

Innovation and product activity

2,049 matched news records

Technology, product and R&D metadata provide an auditable view of the sector's innovation conversation.

Unique news records matching the curated innovation rule
Caution · market restraint

Biosimilars entering the market

1,542 macro/risk records

The extracted restraint and the measured macro-news pulse belong in the downside research frame.

Prism market-growth restraint plus U.S. news metadata
Caution · news pulse

Coverage growth can reverse

+9.8% news volume

The latest 12 months contain 10,786 matched records versus 9,825 in the previous window.

Available Prism coverage through 2026-05-05
Caution · sentiment

Classified tone is not demand

41.7% positive · +4.6pp

Machine-classified news tone is useful context, but it is not revenue, output or a return forecast.

Eight-quarter Prism sentiment series

Opportunity and caution cards are curated research prompts grounded in the counts shown; they are not probabilities, recommendations or forecasts. News coverage runs 2024-01-01–2026-05-05; the latest quarter may be partial.

Explore the broader U.S. industrial landscape →
08 · Scope and sources

How to read this snapshot

Basket and ranking

Five U.S.-listed issuers classified under SEC SIC 2836 (Biological Products, Excluding Disgnostic Substances), selected as the first five names that pass all live publication gates from the Prism readiness candidate pool ranked 11–18. Every candidate has complete cached readiness evidence. This is a research cohort, not a recommendation.

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Evidence used

  • Official annual filingsFY revenue history and latest profitability
  • U.S. exchange market snapshotDated price, 52-week range, P/E, market capitalisation and monthly-close return
  • Fliar BI PrismReadiness, company and industry news, community context and U.S.-scope patent records
  • Prism market-growth extractionDated third-party Biological Products, Excluding Disgnostic Substances Industry in USA market benchmark with source-count, geography and confidence context
Important: Research and educational information only. Not investment advice, a recommendation, or a live-price service. Market figures are dated as of 01 September 2026.
09 · Final derived analysis

Conclusions, comparisons, anomalies, explanations and decisions

A final evidence-linked synthesis of the metrics already displayed above. Every named company opens its actual Companies Radar profile.

Conclusions

Scale and margin leadership sit with BioCryst and BioCryst

BioCryst has the largest displayed latest revenue at $0.88B; BioCryst has the widest displayed latest margin at 30.2%.

Open BioCryst in Companies Radar
Comparisons
Anomalies

Aligos Therapeutics has the widest attention-readiness rank gap

It ranks #4 by measured news attention (13.3%) and #1 by Prism readiness. The gap is a review flag, not evidence that either measure is wrong.

Open Aligos Therapeutics in Companies Radar

Iovance shows a price-operating divergence to inspect

Its displayed filing-revenue change is +22061.6% while its available monthly-close return is -66.4%. The signs differ, but the two measures cover different windows and do not establish causality.

Open Iovance in Companies Radar
Explanations

Attention measures coverage volume, not quality

BioCryst's 37.6% share says it appears most often in the matched Prism corpus. It does not score whether that coverage is favourable or whether the company is investable.

Open BioCryst in Companies Radar

Different windows explain why signals can disagree

Revenue comes from the printed filing periods, price paths use the dated monthly-close windows, and Prism signals use their stated event windows. No causal attribution is made across them.

Research decisions

Verify the readiness leader in Companies Radar

Open Aligos Therapeutics's company profile and inspect the underlying management, market-activity, innovation and risk evidence before relying on the 51/100 score.

Open Aligos Therapeutics in Companies Radar
Method boundary: These are deterministic comparisons of the displayed snapshot fields. They flag relationships for further research, do not establish causality and are not investment recommendations.
Coming soon